FUTURE ONCOLOGY
Volume 6 #3/4 December 31, 2000
Technology Update
SYNTHETIC NUCLEIC ACID SEQUENCE CONSTRUCTS AS ONCOLOGY THERAPEUTICS-PART III
Molecular Targets in Oncology
- C-myc
- Oncomyc-NG (AVI-4126)
- INX-3280
- C-myb
- Raf
- Ras
- Protein Kinases
- Bcl-2
- Vascular Endothelial Growth Factor (VEGF)
- DNA-MeTase (DNA Methyltransferase)
- Ribonucleotide reductase (RNR)
- Insulin-like Growth Factor (IGF)-I -II and IGF-Ir
Other Potential SNAS Interventions in Oncology
- Oncogene Inhibition
- Oncogene bcr-abl
- Murine double-minute 2 (mdm2)
- Modulation of Tumor Suppressor Genes
- Modulation of Signal Tranduction Pathways
- Epidermal growth factor (EGF) and transforming growth factor (TGF)-α
- Prevention of Metastasis
- The α V integrins
- Focal adhesion kinase
- Enhancement of Apoptosis
- Inhibitors of apoptosis proteins (IAP)
- Telomerase Inhibition
- Modulation of Chemotherapeutics
- Immunotherapy
- Viral Inhibition
Diagnostic, Research, and Drug Discovery Applications
Developers of SNAS-Related Pharmaceuticals
- atugen
- AVI BioPharma
- Coley Pharmaceutical Group
- Cytoclonal Pharmaceutics
- EpiGenesis Pharmaceuticals
- Gemini Technologies
- Genta
- Hybridon
- Immusol
- Inex Pharmaceuticals
- Isis Pharmaceuticals
- Lorus Therapeutics
- MethylGene
- Ribozyme Pharmaceuticals (RPI)
| 